Answers are grounded in this paper and cite their sources.
Clinical findings reveal no negative impacts of rheumatoid arthritis on chronic hepatitis C treatment outcomes, suggesting liver health is key.
RA does not contribute to increased severity or progression of HCV-related liver disease and does not negatively affect the effectiveness or safety of DAA therapy. Liver disease stage and hepatic dysfunction, rather than the presence of RA, are the key determinants of treatment outcomes in patients with chronic HCV infection.
No takes yet. Share an insight, caveat, or question.
Brzdęk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: